Skip to content
Politically.com Search all
Menu

HR 340 119th Congress

The HCT/P Modernization Act of 2025

To direct the Secretary of Health and Human Services carry out activities to streamline regulatory oversight of human cell and tissue products, and for other purposes.

Official Title as Introduced Congress.gov

Introduced Jan 13, 2025 Latest action Jan 13, 2025 Sponsor: Rep. Crenshaw, Dan [R-TX-2] Health
Open official Congress.gov record
Source: Congress.govUpdated 2026-09-18 03:51:38 UTC.

Source-linked procedural record

Bill journey

5 dated records

This is a chronology, not a progress score. Politically.com does not classify stages or infer what comes next. Records sharing a date are grouped because not every source field supplies a time.

Congress.gov Recently refreshed U.S. Senate XML Recently refreshed
Introduction 1 One supplied introduction date.
Official actions 3 3 dated action records.
Committees 1 1 undated relationship.
Amendments 0 No record is cached.
Text versions 1 1 dated, 0 without a supplied date.
House roll calls 0 No exact legislation-key match in the House-vote cache.
Senate roll calls 0 No exact document-key match in the Senate-vote cache.
Related measures 2 2 undated relationships.
Linked law 0 No linked law record is cached; this does not predict outcome.
  1. Official action Congress.gov

    Referred to the House Committee on Energy and Commerce.

    IntroReferral · House floor actions · Code H11100

    Open bill record

    Official action Congress.gov

    Introduced in House

    IntroReferral · Library of Congress · Code Intro-H

    Open bill record

    Official action Congress.gov

    Introduced in House

    IntroReferral · Library of Congress · Code 1000

    Open bill record

    Text version Congress.gov

    Introduced in House

    A dated text-version record is available.

    Open text record
View the complete bill journey as an accessible table
Every dated cached record linked to HR 340. Same-date row order does not assert procedural sequence.
Date and timeRecordOfficial detailSource
IntroductionIntroduced Introduced in the House. Congress.gov
Official actionReferred to the House Committee on Energy and Commerce. No additional detail supplied.IntroReferral · House floor actions · Code H11100 Congress.gov
Official actionIntroduced in House No additional detail supplied.IntroReferral · Library of Congress · Code Intro-H Congress.gov
Official actionIntroduced in House No additional detail supplied.IntroReferral · Library of Congress · Code 1000 Congress.gov
Text versionIntroduced in House A dated text-version record is available. Congress.gov

House roll calls join only on matching Congress, legislation type, and number. Senate roll calls join only on matching source-supplied document type and number, not question text. Committee and related-measure relationships have no date in their relationship records and therefore are counted above but never placed on the chronology.

Congressional Research Service

CRS summary

Introduced in House Jan 13, 2025

The HCT/P Modernization Act of 2025This bill requires the Food and Drug Administration (FDA) to provide information to stakeholders and report on the regulation of human cell and tissue products, also referred to as human cells, tissues, or cellular or tissue-based products (HCT/Ps), which are articles containing or consisting of human cells or tissues that are intended for use in a human recipient.The bill requires the FDA to conduct workshops to educate stakeholders and facilitate discussion with them on advancing the science and regulation of human cell and tissue products. The FDA must establish a public docket to receive written comments on this topic, and submit to Congress a report with recommendations on regulating these products. Additionally, the bill requires the FDA to publish on its website educational materials about the Tissue Reference Group and best practices for obtaining a recommendation about products from them. Also, annually for three years, the FDA must publish on its website information on the inquiries submitted and average response times for the Tissue Reference Group, as well as the number of human cell and tissue manufacturers that have registered with the FDA and the number of inspections the FDA has conducted with respect to these manufacturers since 2019. (The Tissue Reference Group is a working group within the FDA that receives product-specific questions from, and provides recommendations for, stakeholders on the regulation of human cell and tissue products under the FDA’s rules.)

Official documents

Text versions